Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Enterprise Value for 7 consecutive years, with -$170.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 82.84% year-over-year to -$170.4 million; the TTM figure through Mar 2026 stood at -$170.4 million (down 82.84% YoY), while the FY2025 annual figure was -$178.8 million, down 83.27% from the prior year.
• Enterprise Value grew to -$170.4 million in Q1 2026 per IKT's latest filing, from -$178.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$3.2 million in Q3 2024 and bottomed at -$178.8 million in Q4 2025.
• Historically, Enterprise Value has averaged -$54.2 million across 5 years, with a median of -$26.5 million in 2022.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 80.73% — and 2025, when it tumbled 2283.81%.
• Inhibikase Therapeutics' Enterprise Value stood at -$23.1 million in 2022, then soared by 42.51% to -$13.3 million in 2023, then sank by 636.06% to -$97.5 million in 2024, then tumbled by 83.27% to -$178.8 million in 2025, then grew by 4.7% to -$170.4 million in 2026.
• Business Quant data shows IKT's Enterprise Value at -$170.4 million in Q1 2026, -$178.8 million in Q4 2025, and -$77.3 million in Q3 2025.